Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday. Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations. The company’s platform helps […]
Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics. Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform.